Buchumschlag

Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis

Disruption of the blood-brain barrier (BBB) is a hallmark of acute inflammatory lesions in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis. This disruption may precede and facilitate the infiltration of encephalitogenic T cells. The signaling events that lead t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lanz, Tobias (VerfasserIn) , Becker, Simon (VerfasserIn) , Osswald, Matthias (VerfasserIn) , Bittner, Stefan (VerfasserIn) , Schuhmann, Michael K. (VerfasserIn) , Opitz, Christiane (VerfasserIn) , Gaikwad, Sadanand (VerfasserIn) , Wiestler, Benedikt (VerfasserIn) , Litzenburger, Ulrike (VerfasserIn) , Sahm, Felix (VerfasserIn) , Ott, Martina (VerfasserIn) , Iwantscheff, Simeon Alexander (VerfasserIn) , Grabitz, Carl Robert (VerfasserIn) , Mittelbronn, Michel (VerfasserIn) , Deimling, Andreas von (VerfasserIn) , Winkler, Frank (VerfasserIn) , Meuth, Sven G. (VerfasserIn) , Wick, Wolfgang (VerfasserIn) , Platten, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 19, 2013
In: Proceedings of the National Academy of Sciences of the United States of America
Year: 2013, Jahrgang: 110, Heft: 36, Pages: 14735-14740
ISSN:1091-6490
DOI:10.1073/pnas.1302569110
Online-Zugang:Verlag, Volltext: https://doi.org/10.1073/pnas.1302569110
Verlag, Volltext: https://www.pnas.org/content/110/36/14735
Volltext
Verfasserangaben:Tobias V. Lanz, Simon Becker, Matthias Osswald, Stefan Bittner, Michael K. Schuhmann, Christiane A. Opitz, Sadanand Gaikwad, Benedikt Wiestler, Ulrike M. Litzenburger, Felix Sahm, Martina Ott, Simeon Iwantscheff, Carl Grabitz, Michel Mittelbronn, Andreas von Deimling, Frank Winkler, Sven G. Meuth, Wolfgang Wick, and Michael Platten
Beschreibung
Zusammenfassung:Disruption of the blood-brain barrier (BBB) is a hallmark of acute inflammatory lesions in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis. This disruption may precede and facilitate the infiltration of encephalitogenic T cells. The signaling events that lead to this BBB disruption are incompletely understood but appear to involve dysregulation of tight-junction proteins such as claudins. Pharmacological interventions aiming at stabilizing the BBB in MS might have therapeutic potential. Here, we show that the orally available small molecule LY-317615, a synthetic bisindolylmaleimide and inhibitor of protein kinase Cβ, which is clinically under investigation for the treatment of cancer, suppresses the transmigration of activated T cells through an inflamed endothelial cell barrier, where it leads to the induction of the tight-junction molecules zona occludens-1, claudin 3, and claudin 5 and other pathways critically involved in transendothelial leukocyte migration. Treatment of mice with ongoing experimental autoimmune encephalomyelitis with LY-317615 ameliorates inflammation, demyelination, axonal damage, and clinical symptoms. Although LY-317615 dose-dependently suppresses T-cell proliferation and cytokine production independent of antigen specificity, its therapeutic effect is abrogated in a mouse model requiring pertussis toxin. This abrogation indicates that the anti-inflammatory and clinical efficacy is mainly mediated by stabilization of the BBB, thus suppressing the transmigration of encephalitogenic T cells. Collectively, our data suggest the involvement of endothelial protein kinase Cβ in stabilizing the BBB in autoimmune neuroinflammation and imply a therapeutic potential of BBB-targeting agents such as LY-317615 as therapeutic approaches for MS.
Beschreibung:Gesehen am 06.10.2021
Beschreibung:Online Resource
ISSN:1091-6490
DOI:10.1073/pnas.1302569110

Ähnliche Einträge